Related Experiment Videos
Antifolates: current developments
1Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520-8032, USA.
Abstract:
In summary, the problem of MTX resistance has been approached in a mechanistic fashion, based on the wealth of information generated over the years. To date, these strategies have produced several new classes of anticancer drugs, with a variety of anticipated and unanticipated mechanisms of action. Several of these have shown promising preclinical activity, and these are moving into more stringent testing in the clinic.
Insights
Researchers are developing new anticancer drugs to overcome methotrexate (MTX) resistance. These novel therapies, based on mechanistic understanding, show promising preclinical activity and are advancing to clinical trials.
Area of Science:
- Oncology
- Pharmacology
- Drug Discovery
Background:
- Methotrexate (MTX) resistance is a significant challenge in cancer therapy.
- Understanding the mechanisms of MTX resistance is crucial for developing effective treatments.
Purpose of the Study:
- To review and summarize strategies for overcoming MTX resistance.
- To highlight novel anticancer drug classes developed through mechanistic approaches.
Main Methods:
- Mechanistic investigations into MTX resistance.
- Preclinical evaluation of newly developed anticancer agents.
Main Results:
- Identification of diverse mechanisms contributing to MTX resistance.
- Development of several new classes of anticancer drugs with varied mechanisms of action.
- Promising preclinical activity observed for these novel drug candidates.
Conclusions:
- Mechanistic insights have successfully guided the development of novel anticancer drugs.
- These new drug classes represent a promising advancement in combating MTX resistance.
- Further clinical testing is warranted to establish the efficacy and safety of these agents.